Drug intelligence / Profile preview

BR005-036C

Development stage: Phase 3
Lead developer: Brise Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

BR005-036C is an orally bioavailable small molecule calcitonin gene-related peptide (CGRP) receptor antagonist being developed by Xiyuan Anjian (Beijing) Medicine for the treatment of migraine. CGRP is a potent neuropeptide that plays a key role in the pathophysiology of migraine by mediating vasodilation and pain transmission in the trigeminovascular system. By blocking the CGRP receptor, BR005-036C aims to provide relief from acute migraine attacks and potentially prevent their occurrence. It belongs to the "gepant" class of migraine medications and is currently undergoing clinical evaluation in China, including Phase 2 trials for acute treatment.

Targets

Calcitonin gene-related peptide type 1 receptor

Beyond the preview

Go deeper on BR005-036C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR005-036C.

Explore the full profile